{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chlamydia-uncomplicated-genital/management/management/","result":{"pageContext":{"chapter":{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 80e67993-1639-4eed-8b90-7c9883f020f3 --><h2>Scenario: Management of uncomplicated genital chlamydia</h2><!-- end field 80e67993-1639-4eed-8b90-7c9883f020f3 -->","summary":"Covers the management of people with signs and symptoms strongly suggestive of chlamydia, or with a positive test result for chlamydia, including notification of sexual partners.","htmlStringContent":"<!-- begin item f22afa93-cefe-4aec-a10f-80c0a04f14e5 --><!-- begin field a5b6dbb6-76d6-4cae-899d-acbc015a56d2 --><p>From age 13 years onwards.</p><!-- end field a5b6dbb6-76d6-4cae-899d-acbc015a56d2 --><!-- end item f22afa93-cefe-4aec-a10f-80c0a04f14e5 -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","lastRevised":"Last revised in January 2021","chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"6007798f-bac1-57fa-8d2a-378317d1ac81","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field aec268ec-022a-41ff-ba5e-a00f236d4183 --><h3>How should I manage a person with suspected or confirmed chlamydia?</h3><!-- end field aec268ec-022a-41ff-ba5e-a00f236d4183 -->","summary":null,"htmlStringContent":"<!-- begin item 4e80dbb9-ff82-45a5-9c6d-38c75455c452 --><!-- begin field 02f0e941-67dd-44fb-ac1f-b61fe18df593 --><ul><li><strong>If chlamydia infection is suspected or confirmed, strongly recommend referral to</strong> <strong>a genito-urinary medicine (GUM) clinic for management.  </strong><strong>If the person declines, or is unable to attend a GUM clinic, manage in primary care:</strong><ul><li>For adults and children over the age of 13 years, prescribe doxycycline 100 mg twice daily for 7 days</li><li>If doxycycline is contraindicated or not tolerated prescribe azithromycin 1 g orally for one day, then 500mg orally once daily for two days or erythromycin 500 mg twice daily for 10–14 days.</li><li>Ofloxacin 200 mg twice daily for seven days, <em>or </em>400 mg once daily for seven days is a possible alternative, but use is contraindicated in children and growing adolescents.</li><li>Doxycycline and ofloxacin are contraindicated in pregnancy. If the woman is pregnant, consider prescribing:<ul><li>Azithromycin, 1 g orally for one day, then 500mg orally once daily for two days, <em>or</em> </li><li>Erythromycin 500 mg four times daily for seven days, <em>or</em> </li><li>Erythromycin 500 mg twice daily for 14 days, <em>or</em> </li><li>Amoxicillin 500 mg three times a day for seven days.</li><li>If there is any uncertainty, seek specialist advice.</li></ul></li><li><div>In people with signs or symptoms strongly suggestive of chlamydia, start treatment without waiting for laboratory confirmation (after testing for chlamydia and other sexually transmitted infections as appropriate). Test of cure (TOC) should also be undertaken for diagnosed rectal infections.</div></li></ul></li><li><strong>Advise that sexual intercourse (including oral sex) should be avoided until the person and their partner(s) have completed treatment (or waited 7 days after treatment with azithromycin).</strong></li><li><strong>Provide w</strong><strong>ritten information</strong> on the natural history of chlamydia infection, its transmission, treatment, and possible complications. A <a data-hyperlink-id=\"9203942f-e0eb-4699-872f-a93100c61fa2\" href=\"http://www.bashh.org/documents/Chlamydia_PIL_DIGITAL_2016.pdf\">patient information leaflet</a> is available from the British Association for Sexual Health and HIV (BASHH).</li><li>Provide written information on safer sex. An information leaflet is available from the <a data-hyperlink-id=\"c1515ee3-8ad7-47fc-8190-a93100c62049\" href=\"http://www.fpa.org.uk/product/safe-sex-and-contraception\">Family Planning Association</a>.</li><li><strong>Strongly encourage all people with confirmed chlamydia infection to be screened for other sexually transmitted infections (STIs),</strong> including gonorrhoea, hepatitis B, HIV, and syphilis. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/\">Gonorrhoea</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-b/\">Hepatitis B</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/\">Syphilis</a>.<ul><li>If antibiotic treatment has been initiated in primary care, STI screening at a GUM clinic should take place at least 1 week after completion of treatment. </li></ul></li><li><strong>Refer all people with confirmed chlamydia infection to a GUM clinic for partner notification.</strong></li><li>If the person is unwilling or unable to attend a GUM clinic, advise them that (with their consent) their details can be provided to the GUM clinic soley for the purposes of partner notification.</li><li>Ensure that the person's current partner is treated for chlamydia irrespective of their screening result.</li><li><strong>Urgently refer the person to GUM if there is no response to first-line treatment.</strong></li><li><strong>Offer repeat testing to all people under the age of 25 years diagnosed with chlamydia 3–6 months after completion of treatment to check for re-infection.</strong></li><li>Consider offering repeat testing to people over the age of 25 years who are at high risk of re-infection</li><li><strong>Refer all women with suspected pelvic inflammatory disease to a GUM clinic.</strong> For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a>.</li><li><strong>Consider the possibility of sexual abuse in any child or young person with chlamydia,</strong> particularly in the following circumstances:<ul><li>The young person is 13–15 years of age, unless there is clear evidence that the STI was acquired from consensual sexual activity with a peer.</li></ul></li><li>The young person is 16–17 years of age and there is no clear evidence that the STI was acquired from consensual sexual activity and/or there is a clear difference in power or mental capacity between the young person and their sexual partner, or there is concern that the young person is being exploited.</li><li>If sexual abuse is suspected, follow appropriate child protection procedures and refer to a paediatrician if necessary. For more information, see the section on recognition of sexual abuse in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/child-maltreatment-recognition-management/\">Child maltreatment - recognition and management</a>.</li></ul><!-- end field 02f0e941-67dd-44fb-ac1f-b61fe18df593 --><!-- end item 4e80dbb9-ff82-45a5-9c6d-38c75455c452 -->","subChapters":[{"id":"3e48a116-e4fb-55f6-8f8e-c15fe76e0004","slug":"basis-for-recommendation-3d2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 386b79ac-4de8-45c1-bf80-6824775ae223 --><h4>Basis for recommendation</h4><!-- end field 386b79ac-4de8-45c1-bf80-6824775ae223 -->","summary":null,"htmlStringContent":"<!-- begin item 3d2dbfa8-9538-4e19-83c1-6c67c24e296d --><!-- begin field b419109d-c2bb-42d1-a2a7-5a7dfd1d990c --><p>The recommendations on management of people with suspected or confirmed chlamydia are based on expert opinion in the British Association for Sexual Health (BASHH) <em>2015 UK national guideline for the management of infection with Chlamydia trachomatis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BASHH, 2015</a>], the BASHH <em>Update on the treatment of Chlamydia trachomatis (CT) infection </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BASHH, 2018</a>], the Royal College of General Practitioners guideline <em>Sexually Transmitted Infections in Primary Care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">RCGP, 2013</a>], and the Health Protection Agency guideline on <em>Diagnosis of Chlamydia trachomatis, Quick Reference Guide for General Practices </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">HPA, 2008</a>].</p><h5>Sexual abuse</h5><ul><li>The information on when to consider child sexual abuse is based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Child maltreatment: when to suspect maltreatment in under 18s </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">NICE, 2009</a>]<em>.</em></li></ul><!-- end field b419109d-c2bb-42d1-a2a7-5a7dfd1d990c --><!-- end item 3d2dbfa8-9538-4e19-83c1-6c67c24e296d -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}